Nutritional Basis for Colonization Resistance by Human Commensal Escherichia coli Strains HS and Nissle 1917 against E. coli O157:H7 in the Mouse Intestine

Escherichia coli is a single species consisting of many biotypes, some of which are commensal colonizers of mammals and others that cause disease. Humans are colonized on average with five commensal biotypes, and it is widely thought that the commensals serve as a barrier to infection by pathogens. Previous studies showed that a combination of three pre-colonized commensal E. coli strains prevents colonization of E. coli O157:H7 in a mouse model (Leatham, et al., 2010, Infect Immun 77: 2876–7886). The commensal biotypes included E. coli HS, which is known to successfully colonize humans at high doses with no adverse effects, and E. coli Nissle 1917, a human commensal strain that is used in Europe as a preventative of traveler's diarrhea. We hypothesized that commensal biotypes could exert colonization resistance by consuming nutrients needed by E. coli O157:H7 to colonize, thus preventing this first step in infection. Here we report that to colonize streptomycin-treated mice E. coli HS consumes six of the twelve sugars tested and E. coli Nissle 1917 uses a complementary yet divergent set of seven sugars to colonize, thus establishing a nutritional basis for the ability of E. coli HS and Nissle 1917 to occupy distinct niches in the mouse intestine. Together these two commensals use the five sugars previously determined to be most important for colonization of E. coli EDL933, an O157:H7 strain. As predicted, the two commensals prevented E. coli EDL933 colonization. The results support a model in which invading pathogenic E. coli must compete with the gut microbiota to obtain the nutrients needed to colonize and establish infection; accordingly, the outcome of the challenge is determined by the aggregate capacity of the native microbiota to consume the nutrients required by the pathogen.

[1]  R. Knabb,et al.  ANNALS OF THE NEW YORK ACADEMY OF SCIENCES , 2014, Annals of the New York Academy of Sciences.

[2]  D. Swallow,et al.  Population Genetics of Lactase Persistence and Lactose Intolerance , 2012 .

[3]  J. Frimodt-Møller,et al.  The Streptomycin-Treated Mouse Intestine Selects Escherichia coli envZ Missense Mutants That Interact with Dense and Diverse Intestinal Microbiota , 2012, Infection and Immunity.

[4]  W. Engst,et al.  Dextran Sodium Sulfate-Induced Inflammation Alters the Expression of Proteins by Intestinal Escherichia coli Strains in a Gnotobiotic Mouse Model , 2011, Applied and Environmental Microbiology.

[5]  Fatema Z. Chowdhury,et al.  Anaerobic Respiration of Escherichia coli in the Mouse Intestine , 2011, Infection and Immunity.

[6]  Wolf-Dietrich Hardt,et al.  Mechanisms controlling pathogen colonization of the gut. , 2011, Current opinion in microbiology.

[7]  C. Josenhans,et al.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models , 2010, Nature Reviews Microbiology.

[8]  U. Dobrindt,et al.  Safety of Probiotic Escherichia coli Strain Nissle 1917 Depends on Intestinal Microbiota and Adaptive Immunity of the Host , 2010, Infection and Immunity.

[9]  Bernard Henrissat,et al.  Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins , 2010, Proceedings of the National Academy of Sciences.

[10]  R. Xavier,et al.  Crohn's disease‐associated adherent‐invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly , 2010, Cellular microbiology.

[11]  J. Plumbridge An Alternative Route for Recycling of N-Acetylglucosamine from Peptidoglycan Involves the N-Acetylglucosamine Phosphotransferase System in Escherichia coli , 2009, Journal of bacteriology.

[12]  Paul S. Cohen,et al.  Precolonized Human Commensal Escherichia coli Strains Serve as a Barrier to E. coli O157:H7 Growth in the Streptomycin-Treated Mouse Intestine , 2009, Infection and Immunity.

[13]  T. Venkatesan Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial. , 2008, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[14]  P. Gajer,et al.  The Pangenome Structure of Escherichia coli: Comparative Genomic Analysis of E. coli Commensal and Pathogenic Isolates , 2008, Journal of bacteriology.

[15]  I. Bjarnason,et al.  Probiotic prophylaxis in predicted severe acute pancreatitis , 2008, The Lancet.

[16]  Michael Schultz,et al.  Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. , 2008, Inflammatory Bowel Diseases.

[17]  Fatema Z. Chowdhury,et al.  Glycogen and Maltose Utilization by Escherichia coli O157:H7 in the Mouse Intestine , 2008, Infection and Immunity.

[18]  Wolf-Dietrich Hardt,et al.  The role of microbiota in infectious disease. , 2008, Trends in microbiology.

[19]  Paul S. Cohen,et al.  Comparison of Carbon Nutrition for Pathogenic and Commensal Escherichia coli Strains in the Mouse Intestine , 2008, Infection and Immunity.

[20]  N. Pace,et al.  Gastrointestinal microbiology enters the metagenomics era , 2008, Current opinion in gastroenterology.

[21]  F. Gunzer,et al.  Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background , 2007, International journal of experimental pathology.

[22]  J. Strathern,et al.  Genetics of Lactase Persistence and Lactose Intolerance , 2008 .

[23]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[24]  T. Conway,et al.  l-Fucose Stimulates Utilization of d-Ribose by Escherichia coli MG1655 ΔfucAO and E. coli Nissle 1917 ΔfucAO Mutants in the Mouse Intestine and in M9 Minimal Medium , 2007, Infection and Immunity.

[25]  Paul S. Cohen,et al.  Respiration of Escherichia coli in the Mouse Intestine , 2007, Infection and Immunity.

[26]  Daniel B. DiGiulio,et al.  Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.

[27]  M. Schmidt,et al.  Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO‐2 and PKCζ redistribution resulting in tight junction and epithelial barrier repair , 2007, Cellular microbiology.

[28]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.

[29]  D. Ledoux,et al.  Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease , 2006, International journal of STD & AIDS.

[30]  R. Welch,et al.  Regulation of Type 1 Fimbriae by Unlinked FimB- and FimE-Like Recombinases in Uropathogenic Escherichia coli Strain CFT073 , 2006, Infection and Immunity.

[31]  Traci Haddock,et al.  Mouse Intestine Selects Nonmotile flhDC Mutants of Escherichia coli MG1655 with Increased Colonizing Ability and Better Utilization of Carbon Sources , 2005, Infection and Immunity.

[32]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[33]  Laurent Beaugerie,et al.  High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. , 2004, Gastroenterology.

[34]  Joe E Grissom,et al.  Carbon nutrition of Escherichia coli in the mouse intestine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Dong-Eun Chang,et al.  Glycolytic and Gluconeogenic Growth of Escherichia coli O157:H7 (EDL933) and E. coli K-12 (MG1655) in the Mouse Intestine , 2004, Infection and Immunity.

[36]  K. Murphy,et al.  Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli , 2003, BMC Molecular Biology.

[37]  B. Wanner,et al.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[39]  R. Mackie,et al.  Developmental microbial ecology of the neonatal gastrointestinal tract. , 1999, The American journal of clinical nutrition.

[40]  T. Conway,et al.  What’s for Dinner?: Entner-Doudoroff Metabolism inEscherichia coli , 1998, Journal of bacteriology.

[41]  M. Levine,et al.  Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. , 1995, The Journal of infectious diseases.

[42]  G R Jacobson,et al.  Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. , 1993, Microbiological reviews.

[43]  D. van der Waaij,et al.  Determination of colonization resistance of the digestive tract by biotyping of Enterobacteriaceae , 1990, Epidemiology and Infection.

[44]  A. Rimm,et al.  Transplant or chemotherapy in acute myelogenous leukaemia , 1989 .

[45]  R. Simmons,et al.  Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria , 1987, Infection and immunity.

[46]  R. Freter,et al.  Models for studying the role of bacterial attachment in virulence and pathogenesis. , 1983, Reviews of infectious diseases.

[47]  R. Freter,et al.  Continuous-flow cultures as in vitro models of the ecology of large intestinal flora , 1983, Infection and immunity.

[48]  R. Freter,et al.  Survival and Implantation of Escherichia coli in the Intestinal Tract , 1983, Infection and immunity.

[49]  R. Freter,et al.  Mechanisms That Control Bacterial Populations in Continuous-Flow Culture Models of Mouse Large Intestinal Flora , 1983, Infection and immunity.

[50]  R. Freter,et al.  Experimental and Mathematical Models of Escherichia coli Plasmid Transfer In Vitro and In Vivo , 1983, Infection and immunity.

[51]  D. Tilman Resource competition and community structure. , 1983, Monographs in population biology.

[52]  M. Levine,et al.  Failure to detect conventional enterotoxins in classical enteropathogenic (serotyped) Escherichia coli strains of proven pathogenicity , 1982, Infection and immunity.

[53]  Daniel S Waterman,et al.  ESCHERICHIA COLI STRAINS THAT CAUSE DIARRHŒA BUT DO NOT PRODUCE HEAT-LABILE OR HEAT-STABLE ENTEROTOXINS AND ARE NON-INVASIVE , 1978, The Lancet.

[54]  F. Neidhardt,et al.  Culture Medium for Enterobacteria , 1974, Journal of bacteriology.

[55]  H. Dupont,et al.  EXPERIMENTAL MODELS IN THE INVESTIGATION OF THE VIRULENCE OF DYSENTERY BACILLI AND ESCHERICHIA COLI * , 1971 .

[56]  S. Formal,et al.  EXPERIMENTAL SHIGELLA INFECTIONS: CHARACTERISTICS OF A FATAL INFECTION PRODUCED IN GUINEA PIGS , 1958, Journal of bacteriology.

[57]  L. S. Clark,et al.  The effect of streptomycin on oxygen uptake and viability of resting suspensions of Escherichia coli. , 1953, Science.

[58]  I. L. Barkulis INHIBITION OF THE ANAEROBIC PYRUVATE METABOLISM OF ESCHERICHIA COLI BY DIHYDROSTREPTOMYCIN, , , 1953, Journal of bacteriology.

[59]  A. Nissle [Mutaflor and its medical significance]. , 1951, Zeitschrift fur klinische Medizin.

[60]  R. J. Henry,et al.  The effect of streptomycin on the metabolism of multiplying bacteria. , 1949, Journal of bacteriology.

[61]  W. Umbreit A site of action of streptomycin. , 1949, The Journal of biological chemistry.